ScreenerHero

SLDBSolid Biosciences Inc.

NAS · US · Healthcare · Biotechnology · solidbio.com
9.300USD-4.52%Mkt Cap: 997.19M $P/E: —

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrop…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap997.19M $
Enterprise Value618.23M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-174.32M $
Revenue/Share—
Last Price9.300 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees121
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.21
PEG—
EV/EBITDA-2.94
EV/Revenue—
P/S—
P/B2.56
EPS (TTM)-1.76
EPS (Forward)-1.75
52W Range
3.79072% of range11.44
52W High11.44 USD
52W Low3.790 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-96.84%
ROA-74.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-156.29M $
CapEx (TTM)1.15M $
FCF Margin—
FCF Yield-11.86%
Net Debt-357.52M $
Net Debt/EBITDA1.70
Balance Sheet
Debt/Equity0.12
Current Ratio13.82
Quick Ratio13.21
Book Value/Sh3.558 USD
Cash/Share3.522 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateOct 28, 2022
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.64 USD
Upside (mean)+89.6%
Target Range11.00 USD – 26.00 USD
$11.00+89.6% to mean$26.00
# Analysts11
Ownership
Shares Out.107.23M
Float64.81M
Insiders0.68%
Institutions107.28%
Short Interest
Short Ratio12.6d
Short % Float18.47%
Short % Out.16.21%
Shares Short17.04M
Short (prev mo.)18.27M
Technical
SMA 508.861 (+5.0%)
SMA 2007.011 (+32.6%)
Beta2.42
S&P 52W Chg18.16%
Avg Vol (30d)982.05K
Avg Vol (10d)884.65K
Technical Indicators
RSI (14)57.1
MACD0.1777
MACD Signal0.0632
MACD Hist.+0.1146
BB Upper9.687 USD
BB Middle8.581 USD
BB Lower7.475 USD
BB Width25.77%
ATR (14)0.4957 USD
Vol Ratio (20d)0.84x